MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.vaccine.2022.02.065

Медицинская библиотека · Vaccine · 2022

Safety and reactogenicity of a liquid formulation of human rotavirus vaccine (porcine circovirus-free): A phase III, observer-blind, randomized, multi-country study.

Lau Yu-Lung, Fan Leung Ting, Sirvan Cetin Benhur, Cagri Dinleyici Ener, Huang Li-Min, Halperin Scott A, Hsiao Chien-Chou, Tapiero Bruce, Tipton Mary, Campbell James D, Moerman Leentje, Povey Michael, Bi Dan, Singh Tina, Rota-096 study group

Клиническое исследование III фазыСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

The introduction of rotavirus vaccines in national immunization programs has decreased mortality and hospitalizations due to diarrhea. GSK's live-attenuated, human rotavirus vaccine (HRV) is a 2-dose vaccine for oral administration. Following the detection of porcine circovirus type 1 (PCV-1) in HRV, a PCV-free (no detection of PCV-1 and PCV-2 according to the detection limits of tests used) HRV was developed. The immunogenicity, reactogenicity and safety of a liquid (liq) PCV-free HRV were assessed in two prior studies. The present study aimed to generate additional reactogenicity and safety data.

METHODS

This phase III, observer-blind, randomized, controlled multi-country study enrolled healthy 6-12-week-old infants. Infants were randomized to receive 2 doses of either the liq PCV-free HRV (N = 677) or the lyophilized (lyo) HRV (N = 674) 1-2 months apart. Solicited adverse events (AEs) were recorded for 8 days after each dose, unsolicited AEs for 31 days and serious AEs (SAEs) from dose 1 until the end of the 6-month safety follow-up.

RESULTS

The occurrence of solicited general AEs was comparable between the liq PCV-free HRV and the lyo HRV groups, with irritability/fussiness being the most frequently reported (74.9% [95% confidence interval: 71.4-78.1] and 72.1% [68.6-75.5]). Unsolicited AEs were reported for 29.7% (26.3-33.3) and 30.6% (27.1-34.2) of infants in the liq PCV-free HRV and the lyo HRV group. A total of 39 and 38 infants reported at least one SAE, respectively. The most common SAEs were upper respiratory tract (0.7% and 0.9%) and urinary tract infections (0.9% and 0.6%). One SAE (constipation) in the liq PCV-free HRV group was considered as potentially causally related to vaccination by the investigator. No deaths were reported.

CONCLUSIONS

The study showed that the reactogenicity and safety profiles of the liq PCV-free HRV and the lyo HRV are similar.

CLINICALTRIALS: gov identifier: NCT0395474.

Для цитирования: Lau Yu-Lung, Fan Leung Ting, Sirvan Cetin Benhur, Cagri Dinleyici Ener, Huang Li-Min, Halperin Scott A, Hsiao Chien-Chou, Tapiero Bruce, Tipton Mary, Campbell James D, Moerman Leentje, Povey Michael, Bi Dan, Singh Tina, Rota-096 study group. Safety and reactogenicity of a liquid formulation of human rotavirus vaccine (porcine circovirus-free): A phase III, observer-blind, randomized, multi-country study.. Vaccine. 2022. DOI: 10.1016/j.vaccine.2022.02.065.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.